A Phase 1/2a Multi-Center Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 in combination with pembrolizumab or binimetinib in Adult Patients with Advanced Solid Tumors
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
